Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Commercial launch of INPEFA^® (sotagliflozin) as a differentiated, new treatment option for heart failure patients shows meaningful progress in Q3 with increasing demand across the cardiology community

Read more at globenewswire.com